Regeneron (REGN)
NASDAQ:REGN
Want to see REGN full AI Analyst Report?
REGN Stock Chart & Stats
$750.57
$9.02(1.24%)
At close: 4:00 PM EST
$750.57
$9.02(1.24%)
Day’s Range― - ―
52-Week Range$476.49 - $821.11
Previous CloseN/A
Volume208.99K
Average Volume (3M)586.67K
Market Cap
$73.52B
Enterprise Value$72.01B
Total Cash (Recent Filing)$8.75B
Total Debt (Recent Filing)$2.71B
Price to Earnings (P/E)27.6
Beta0.67
Next Earnings
Jul 30, 2026EPS Estimate
10.88Next Dividend Ex-DateN/A
Dividend Yield0.45%
Share Statistics
EPS (TTM)42.53
Shares Outstanding103,021,890
10 Day Avg. Volume598,446
30 Day Avg. Volume586,674
Financial Highlights & Ratios
PEG Ratio3.38
Price to Book (P/B)2.58
Price to Sales (P/S)5.63
P/FCF Ratio19.79
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue4.83
Enterprise Value/Gross Profit5.71
Enterprise Value/Ebitda12.53
Forecast
1Y Price Target
$881.33Price Target Upside17.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
EPS Forecast (FY)46.2
Revenue Forecast (FY)$15.90B
Bulls Say, Bears Say
Bulls Say
Dupixent Franchise ExpansionAnalyst highlights continued sales strength and ongoing label expansions for Dupixent, framing the product as a durable growth engine that functions like an internal pipeline through new indications.
Eylea Labeling And DeliveryAnalyst notes that labeling improvements for the high-dose Eylea formulation, including a prefilled syringe and a monthly dosing option, could accelerate physician adoption and help defend market share against biosimilars.
Other Revenue ContributionAnalyst emphasizes that Other Revenue from Ilaris and Arcalyst makes up a meaningful portion of operating income and can provide incremental, lower-risk support to reported earnings each quarter.
Bears Say
Biosimilar And Competitor ErosionAnalyst cautions that biosimilar entrants and competing products could materially erode Other Revenue and key franchise sales over time, presenting a longer-term headwind to earnings.
Clinical Differentiation RiskAnalyst notes that late-stage immuno-oncology programs, including LAG-3 and the fianlimab combination, must demonstrate clear efficacy and safety advantages over incumbent therapies to achieve meaningful physician adoption.
Inventory-driven Revenue PressureAnalyst warns that elevated distributor and channel inventories for Eylea are likely to depress near-term reported revenues as shipments translate into delayed recognized sales.
Regeneron News
REGN FAQ
What was Regeneron’s price range in the past 12 months?
Regeneron lowest stock price was $476.49 and its highest was $821.11 in the past 12 months.
What is Regeneron’s market cap?
Regeneron’s market cap is $73.52B.
When is Regeneron’s upcoming earnings report date?
Regeneron’s upcoming earnings report date is Jul 30, 2026 which is in 86 days.
How were Regeneron’s earnings last quarter?
Regeneron released its earnings results on Apr 29, 2026. The company reported $9.47 earnings per share for the quarter, beating the consensus estimate of $8.914 by $0.556.
Is Regeneron overvalued?
According to Wall Street analysts Regeneron’s price is currently Undervalued.
Does Regeneron pay dividends?
Regeneron pays a Quarterly dividend of $0.88 which represents an annual dividend yield of 0.45%. See more information on Regeneron dividends here
What is Regeneron’s EPS estimate?
Regeneron’s EPS estimate is 10.88.
How many shares outstanding does Regeneron have?
Regeneron has 103,021,890 shares outstanding.
What happened to Regeneron’s price movement after its last earnings report?
Regeneron reported an EPS of $9.47 in its last earnings report, beating expectations of $8.914. Following the earnings report the stock price went down -6.206%.
Which hedge fund is a major shareholder of Regeneron?
Currently, no hedge funds are holding shares in REGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Regeneron Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$881.33 (17.42% Upside)
$881.33 (17.42% Upside)
Blogger Sentiment
Bullish
REGN Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 106.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.00%
12-Months-Change
Fundamentals
Return on Equity
14.32%
Trailing 12-Months
Asset Growth
8.85%
Trailing 12-Months
Company Description
Regeneron
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
REGN Company Deck
REGN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call conveyed a predominantly positive operational and financial picture: strong double-digit revenue and EPS growth, robust performance of core growth drivers (DUPIXENT, EYLEA HD, Libtayo), meaningful pipeline and regulatory milestones (including a gene therapy approval and encouraging Phase III data), a healthy balance sheet and active capital return via buybacks. The principal negatives were product-specific pressures (notably a steep decline in legacy EYLEA sales due to conversion, competition and inventory effects), a temporary manufacturing interruption that reduced GAAP margins and a missed FDA action on an EYLEA HD fill-finish application that creates near-term regulatory timing uncertainty. Overall, the call emphasized execution, pipeline progress and financial strength, with manageable near-term operational and regulatory headwinds.View all REGN earnings summariesREGN Revenue Breakdown
43.99% Net product sales
51.11% Collaboration revenue
4.90% Other revenue
REGN Stock 12 Month Forecast
Average Price Target
$881.33
▲(17.42% Upside)
Technical Analysis
Ownership Overview
1.98% Insiders
25.26% Mutual Funds
3.36% Other Institutional Investors
40.14% Public Companies and Individual Investors